Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric A Ross

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Oncotarget|October 21, 2015
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancerEmmanuelle Nicolas, Sanjeevani Arora, Yan Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
European Urology Oncology|March 14, 2020
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerBenjamin Miron, Jean H Hoffman-Censits, Fern Anari, et al.
BMC Medical Genomics|October 13, 2012
Defining the genomic signature of the parous breastSuraj Peri, Ricardo López de Cicco, Julia Santucci-Pereira, et al.
Clinical Colorectal Cancer|September 25, 2020
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal CancerArthur Winer, Crystal S Denlinger, Namrata Vijayvergia, et al.
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Patient Education and Counseling|May 13, 2014
Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) studyLinda Fleisher, Dominique G Ruggieri, Suzanne M Miller, et al.
The Journal of Urology|February 4, 2021
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialMatthew Zibelman, Aeen M Asghar, Daniel C Parker, et al.
Cancer Biology & Therapy|January 22, 2005
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutationsRadka Stoyanova, Margie L Clapper, Alfonso Bellacosa, et al.
European Urology|July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 TrialElizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Oncotarget|October 21, 2015
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancerEmmanuelle Nicolas, Sanjeevani Arora, Yan Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
European Urology Oncology|March 14, 2020
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerBenjamin Miron, Jean H Hoffman-Censits, Fern Anari, et al.
BMC Medical Genomics|October 13, 2012
Defining the genomic signature of the parous breastSuraj Peri, Ricardo López de Cicco, Julia Santucci-Pereira, et al.
Clinical Colorectal Cancer|September 25, 2020
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal CancerArthur Winer, Crystal S Denlinger, Namrata Vijayvergia, et al.
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Patient Education and Counseling|May 13, 2014
Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) studyLinda Fleisher, Dominique G Ruggieri, Suzanne M Miller, et al.
The Journal of Urology|February 4, 2021
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialMatthew Zibelman, Aeen M Asghar, Daniel C Parker, et al.
Cancer Biology & Therapy|January 22, 2005
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutationsRadka Stoyanova, Margie L Clapper, Alfonso Bellacosa, et al.
European Urology|July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 TrialElizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Pageof 10